UiPath launches a pro bono automation project with the Mater Hospital to free up nurses dealing with infection control including Covid-19
26.3.2020 15:00:00 EET | Business Wire | Press release
Today UiPath is launching a pro bono automation project with the Mater Misericordiae University Hospital. The initiative will see software robots assigned to the Infection Prevention and Control (IPC) Department at the Mater. This development will significantly reduce the administrative strain placed upon the department by multidrug resistant organisms or viruses such as Covid-19, enabling IPC nurses to spend more time with patients. The project will see the Mater offered free trial robot licenses for the IPC Department until the end of the year.
With data being automated through software robots, the information will be processed in a fraction of the current time, disseminating patient results in minutes. It will save the infection control department 3 hours per day, 18 hours per week and 936 hours a year which they can now spend managing the current Covid-19 pandemic.
As a result of Covid-19, the Mater expects to receive hundreds of swabs and microbiology tests in the coming months which the software robots can assist in rapid processing. The results can then be distributed to healthcare workers rapidly and essential infection prevention and control measures can be put into action.
Jincy Jerry, Assistant Director of Nursing, Infection Prevention and Control, MMUH, said: “Given that IPC nurses spend close to 30% of their day with administrative tasks, for the past few months I have been looking at ways to make software robots part of our daily jobs. With the COVID-19 pandemic unfolding now, it is crucial that all frontline staff are freed up as much as possible to spend time with patients and deal with this outbreak, rather than being in front of computers.”
“Not only will automation help with this, but it will also take the strain off the hospital as it continues to process huge amounts of more routine patient data in addition to Covid-19 specific information.”
“As we’ve already seen, alongside the public playing their part in physical distancing, fast diagnosis and appropriate self-isolation are crucial to preventing the spread of COVID-19. We’re confident that the project we’re embarking on will help mitigate the huge strain this outbreak is putting on healthcare organisations – not just in MMUH, but across Ireland.”
Mark O’Connor, Public Sector Director Ireland at UiPath, said: “Infection Prevention & Control is critical to help people stay healthy, and while COVID-19 is top of mind, this project will continue to deliver benefits long term. At this time of heightened stress and anxiety, it’s vital to free up doctors and nurses’ time for patients wherever it can be done.”
“Robotic process automation minimises, if not removes, the need for people to carry out repetitive, rules-based admin work – speeding up processes and ensuring they’re error-free. With a robot for every nurse approach, essential frontline staff will be freed to be nurses and not system administrators, being able to focus more on the quality of care – which can make a real difference when it comes to treating patients in times of need.”
O’Connor will be hosting a webinar on April 2, 2020 at 10 a.m. EST/3 p.m. BST to discuss Mater’s use of automation to respond to Covid-19-related scenarios. To register, visit this link.
For more information on UiPath, go to uipath.com.
About UiPath
UiPath is leading the era of “Automation First” by betting on a robot for each person and allowing robots to learn new skills through artificial intelligence (AI) and machine learning (ML). Through free and open training, UiPath brings digital era skills to millions of people around the world, improving business productivity and efficiency, employee engagement, and customer experience.
The company’s hyper-automation platform combines the number one Robotic Process Automation (RPA) solution with a full suite of capabilities, including process mining and analytics, that enable every organization to scale digital business operations at unprecedented speed. The company has already automated millions of repetitive, mind-numbing tasks for businesses and government organizations all over the world, including more than 50% of the Fortune 500 and 8 of the Fortune 10.
UiPath has recently been recognised as the top company in The Deloitte Technology Fast 500 for 2019, a ranking of the fastest growing public and private technology companies in North America, and number 3 in the 2019 Forbes Cloud 100.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200326005081/en/
Contact information
Toni Iafrate
UiPath
toni.iafrate@uipath.com
978-239-5499
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
